New MRI dye could spot prostate cancer more clearly

NCT ID NCT04286386

Ongoing Diagnosis Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing whether a special MRI contrast called hyperpolarized pyruvate can help doctors see prostate tumors more clearly than standard MRI. About 130 men with prostate cancer will receive the contrast before imaging. The goal is to improve cancer detection and diagnosis, not to treat the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Hyperpolarized Carbon C 13 Pyruvate
What this could lead to: If successful, this could lead to a more accurate MRI method for detecting prostate cancer, potentially reducing unnecessary biopsies.
What could go wrong: This is an early-stage imaging study, not a treatment trial. The new contrast may not prove more effective than standard MRI, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE ADENOCARCINOMA

Contacts and locations

Locations

M D Anderson Cancer Center

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.